Heparin dose during percutaneous coronary intervention: How low dare we go?

Heart

Volumn 88, Issue 4, 2002, Pages 331-334

  Niccoli, G ^a   Banning, Adrian P ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; THROMBIN INHIBITOR; TICLOPIDINE; WARFARIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG EFFICACY; DRUG MEGADOSE; HEPARINIZATION; HUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SALVAGE THERAPY; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0036785928     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.88.4.331     Document Type: Review

References (56)

1. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and thrombosis: basic principles and clinical practice, 3rd ed. Philadelphia: JB Lippincott Co, 1994:837-60.
2. Topol E, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-9.
3. Grayburn P, Willard J, Brickner M, et al. In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: evidence for inadequate heparinization. Cathet Cardiov Diagn 1991;23:141-3.
4. Heras M, Chesebro J, Penny W, et al. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988;78:654-60.
5. Chesebro JH, Badimon L, Fuster V. Importance of antithrombin therapy during coronary angioplasty. J Am Coll Cardiol 1991;17(suppl B):96B-100B.
6. Oltrona L, Eisenberg P, Lasala J, et al. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064-71.
7. Pineo G, Hull R. Unfractionated and low molecular weight heparin: comparisons and current recommendations. Med Clin North Am 1998;82:587-99.
8. Young E, Podor TJ, Vemer T, et al. Induction of acute phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 1997;17:1568-74.
9. Hirsch J, Anand SS, Halperin JL, et al. Guide to anti-coagulant therapy: heparin. A statement for health care profesionals from the American Heart Association. Circulation 2001;103:2994-3018.
10. Becker RC. Hirudin-based anticoagulation strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting. J Thromb Thrombolysis 2000;10(suppl 1):59-68.
11. Matthai WH Jr. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(suppl 1):57-60.
12. Blumenthal RS, Carter AJ, Resar JR, et al. Comparison of bedside and hospital laboratory coagulation studies during and after coronary intervention. Cathet Cardiovasc Diagn 1995;35:9-17.
13. Avendano A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:907-10.
14. Bowers J, Ferguson JJ, III. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol 1994;17:357-60.
15. Ferguson JJ. All ACTs are not created equal [editorial] Texas Heart Inst J 1992;19:1-3.
16. Dougherty K, Gaos C, Bush H, et al. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992;26:260-3.
17. Owings JT, Pollock ME, Gosselin RC, et al. Anticoagulation of children undergoing cardiopulmonary bypass is overstimated by current monitoring techniques. Arch Surg 2000;135:1042-7.
18. Helft G, Bartolomeo P, Zaman AG, et al. The heparin management test: a new device for monitoring anticoagulation during coronary intervention. Thromb Res 1999;96:481-5.
19. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines) - executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001;15:2215-38.
20. Swanson N, Hogrefe K, Stephens A, et al. Current perspectives on British use of adjunctive therapies during coronary interventions. Int J Cardiol 2001;79:119-25.
21. Knight CJ, Panesar M, Wilson DJ, et al. Increased platelet responsivenes following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis. Eur Heart J 1998;19:1239-48.
22. Mabin TA, Holmes DR, Smith HC. Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;5:198-202.
23. Waller BF, Fry ET, Peters TF, et al. Abrupt (< 1 day), acute (< 1 week), and early (< 1 month) vessel closure at the angioplasty site. Morphologic observations and causes of closure in 130 necropsy patients undergoing coronary angioplasty. Clin Cardiol 1996;19:857-68.
24. Bull B, Korpman R, Huse W, et al. Heparin therapy during extracorporeal circulation: problems inherent in existing heparin protocols. J Thorac Cardiovas Surg 1975;69:674-84.
25. Young J, Kisker C, Doty D. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearence of fibrin monomer. Ann Thorac Surg 1978;26:231-40.
26. Ferguson J, Dougherty K, Gaos J, et al. Relation between procedural activated clotting time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-5.
27. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-71.
28. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-6.
29. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-6.
30. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-88.
31. Muller C, Buttner H, Petersen J, et al. A randomised comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000;101:590-3.
32. Boccara A, Benamer H, Juliard JM, et al. A randomized trial of a fixed high dose vs a weight-adjusted dose of intravenous heparin during coronary angioplasty. Eur Heart J 1997;18:631-5.
33. Koch KT, Piek JJ, de Winter RJ, et al. Safety of low dose heparin in elective coronary angioplasty. Heart 1997;77:517-22.
34. Koch KT, Piek JJ, de Winter RJ, et al. Two hour ambulation after coronary angioplasty and stenting with 6 F guiding catheters and low dose heparin. Heart 1999;81:53-6.
35. Kaluski E, Krakover R, Cotter G, et al. Minimal heparinization in coronary angioplasty - how much heparin is really warranted? Am J Cardiol 2000;85:953-6.
36. Godon P, Rioufol G, Finet G, et al. Efficacy and safety of low-dose heparin (30 IU/kg) during coronary angioplasty. Arch Mal Coeur Vaiss 2001;94:984-8.
37. National Institute for Clinical Excellence. Guidance on the use of glycoprotein IIb-IIIa inhibitors in the treatment of acute coronary syndromes. National Institute for Clinical Excellence technology appraisal guidance. Number 12, September 2000:1.
38. Knight CJ. National Institute for Clinical Excellence guidance: too NICE to glycoprotein IIb/IIIa inhibitors? Heart 2001;85:481-3.
39. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
40. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary or directional atherectom (the EPIC trial). Evaluation of c7E3 Fab in the prevention of ischemic complications trial. Am J Cardiol 1995;75:559-62.
41. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
42. EPISTENT investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
43. Ambrose JA, Doss R, Geagea JPM, et al. Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention. Am J Cardiol 2001;87:1231-3.
44. Mandak JS, Blankenship JC, Gardner LH, et al. Modifiable risk factors for vascular access site complications in the impact II trial of angioplasty with versus without eptifibatide. J Am Coll Cardiol 1998;31:1518-24.
45. Turpie AGG. Successors to heparin: new antithrombotic agents. Am Heart J 1997;134:S71-7.
46. Antman EM, Handin R. Low-molecular weight heparins. An intriguing new twist with profound implications. Circulation 1998;98:87-9.
47. Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J Am Coll Cardiol 1996;28:1437-43.
48. Grines CL. Anticoagulation requirements for coronary interventions and the role of low molecular weight heparins. J Invas Cardiol 1999;11:7A-12A.
49. Kereiakes DJ, Fry E, Matthai W, et al. Safety of enoxaparin-abciximab combination for percutaneous coronary intervention: preliminary results of the NICE 4 trial [abstract]. Am J Cardiol 1999;84:67P.
50. Collet JPh, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pre-treatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
51. Greiber S, Weber U, Galle J. Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular weight heparin in hemodialysis. Nephron 1997;76:15-19.
52. Antman EM. The search for replacement for unfractionated heparin. Circulation 2001;103:2310-14.
53. Serruys PW, Herrman JPR, Simon R, et al for the HELVETICA investigators. A comparison of hirudin with heparin in the prevention of I restenosis after coronary angioplasty. N Engl J Med 1995;333:757-63.
54. Bittl JA, Strony J, Brinker JA, et al for the HIRULOG Angioplasty Study Investigators. N Engl J Med 1995;333:764-9.
55. Topol EJ. Evolution of improved antithrombotic and antiplatelet agents: genesis of the comparison of abciximab complications with hirulog (and back-up abciximab) events trial (CACHET). Am J Cardiol 1998;82:63P-68P.
56. Bates ER. Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Current Cardiology Reports 2001;3:348-54.